NSAID Use and Incident Cognitive Impairment in a Population-based Cohort

Alzheimer Disease and Associated Disorders

Volumn 30, Issue 2, 2016, Pages 105-112

  Wichmann, Margarete A ^a,d,e   Cruickshanks, Karen J ^a,b   Carlsson, Cynthia M ^d,g   Chappell, Rick ^c,d,f   Fischer, Mary E ^b   Klein, Barbara E K ^b   Klein, Ronald ^b   Schubert, Carla R ^b  

^a Population Health Sciences   (United States)

^b Departments of Ophthalmology and Visual Sciences   (United States)

^c Departments of Biostatistics and Medical Informatics   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e Institute on Aging   (United States)

^f University of Wisconsin Madison   (United States)

^g Education and Clinical Center   (United States)

Author keywords

aspirin; cognition; dementia; nonsteroidal anti inflammatory drug; population based

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN E4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

AGED; ANGINA PECTORIS; ARTHRITIS; ARTICLE; BODY MASS; CEREBROVASCULAR ACCIDENT; COGNITION ASSESSMENT; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DIABETES MELLITUS; DIGIT SYMBOL SUBSTITUTION TEST; DRINKING BEHAVIOR; DRUG USE; EDUCATIONAL STATUS; EXERCISE; FEMALE; FOLLOW UP; HEALTH STATUS; HEART INFARCTION; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROPROTECTION; POPULATION RESEARCH; PRIMARY PREVENTION; PRIORITY JOURNAL; REY AUDITORY VERBAL LEARNING TEST; SHORT FORM 36; SMOKING; TRAIL MAKING TEST; TREATMENT DURATION; INCIDENCE; PROSPECTIVE STUDY; RISK FACTOR;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COGNITIVE DYSFUNCTION; DEMENTIA; FEMALE; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84973171210     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0000000000000098     Document Type: Article

References (40)

1. Zhou Y, Boudreau DM, Freedman AN. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general US population. Pharmacoepidemiol Drug Saf. 2014;23:43-50.
2. Szekely CA, Zandi PP. Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence. CNS Neurol Disord Drug Targets. 2010;9:132-139.
3. McGeer PL, McGeer E, Rogers J, et al. Anti-inflammatory drugs and Alzheimer disease. Lancet. 1990;335:1037-1037.
4. Stewart WF, Kawas C, Corrada M, et al. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 1997;48:626-632.
5. Cote S, Carmichael PH, Verreault R, et al. Nonsteroidal antiinflammatory drug use and the risk of cognitive impairment and Alzheimer's disease. Alzheimers Dement. 2012;8:219-226.
6. Vlad SC, Miller DR, Kowall NW, et al. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology. 2008;70:1672-1677.
7. in't Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001;345:1515-1521.
8. Szekely CA, Breitner JCS, Fitzpatrick AL, et al. NSAID use and dementia risk in the cardiovascular health study - role of APOE and NSAID type. Neurology. 2008;70:17-24.
9. Zandi PP, Anthony JC, Hayden KM, et al. Reduced incidence of AD with NSAID but not H-2 receptor antagonists - the Cache County Study. Neurology. 2002;59:880-886.
10. Arvanitakis Z, Grodstein F, Bienias JL, et al. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology. 2008;70:2219-2225.
11. Breitner JCS, Haneuse S, Walker R, et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology. 2009;72:1899-1905.
12. Breitner J, Baker L, Drye L, et al. Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) The Alzheimer's Disease Antiinflammatory Prevention Trial Research Group. Alzheimers Dement. 2013;9:714-723.
13. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression - a randomized controlled trial. JAMA. 2003;289:2819-2826.
14. Thal LJ, Ferris SH, Kirby L, et al. A randomized, doubleblind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005;30:1204-1215.
15. Cornelius C, Fastbom J, Winblad B, et al. Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population. Neuroepidemiology. 2004;23:135-143.
16. Kang JH, Cook N, Manson J, et al. Low dose aspirin and cognitive function in the women's health study cognitive cohort. Br Med J. 2007;334:987-990.
17. Price JF, Stewart MC, Deary IJ, et al. Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial. Br Med J. 2008;337:a1198.
18. de Craen AJM, Gussekloo J, Vrijsen B, et al. Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia. Am J Epidemiol. 2005;161:114-120.
19. Klein R, Klein BEK, Linton KLP, et al. The Beaver Dam Eye Study: visual acuity. Ophthalmology. 1991;98:1310-1315.
20. Cruickshanks KJ, Wiley TL, Tweed TS, et al. Prevalence of hearing loss in older adults in Beaver Dam, Wisconsin: The Epidemiology of Hearing Loss Study. Am J Epidemiol. 1998;148:879-886.
21. Cruickshanks KJ, Tweed TS, Wiley TL, et al. The 5-year incidence and progression of hearing loss: the Epidemiology of Hearing Loss Study. Arch Otolaryngol Head Neck Surg. 2003;129:1041-1046.
22. Cruickshanks KJ, Nondahl DM, Tweed TS, et al. Education, occupation, noise exposure history and the 10-yr cumulative incidence of hearing impairment in older adults. Hear Res. 2010;264:3-9.
23. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
24. Mitchell JL, Cruickshanks KJ, Klein BEK, et al. Postmenopausal hormone therapy and its association with cognitive impairment. Arch Intern Med. 2003;163:2485-2490.
25. Wichmann MA, Cruickshanks KJ, Carlsson CM, et al. Longterm systemic inflammation and cognitive impairment in a population-based cohort. J Am Geriatr Soc. 2014;62:1683-1691.
26. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270-279.
27. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-269.
28. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
29. Borhani NO, Kass EH, Langford HG, et al. The hypertension detection and follow-up program. Prev Med. 1976;5:207-215.
30. Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769-779.
31. US Food and Drug Administration. Analysis and recommendations for agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. Available at: http:// www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrug SafetyInformationforPatientsandProviders/ucm106201.pdf. Accessed April 8, 2014.
32. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107:1303-1307.
33. Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease - a double-edged sword. Neuron. 2002;35:419-432.
34. Scherder EJA. Low use of analgesics in Alzheimer's disease: possible mechanisms. Psychiatry. 2000;63:1-12.
35. Iso H, Hennekens CH, Stampfer MJ, et al. Prospective study of aspirin use and risk of stroke in women. Stroke. 1999;30:1764-1771.
36. Gorelick PB, Weisman SM. Risk of hemorrhagic stroke with aspirin use - an update. Stroke. 2005;36:1801-1807.
37. Vernooij MW, Haag MDM, van der Lugt A, et al. Use of antithrombotic drugs and the presence of cerebral microbleeds the Rotterdam Scan Study. Arch Neurol. 2009;66: 714-720.
38. Charidimou A, Werring DJ. Cerebral microbleeds and cognition in cerebrovascular disease: an update. J Neurol Sci. 2012;322:50-55.
39. Szekely CA, Green RC, Breitner JC, et al. No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology. 2008;70:2291-2298.
40. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease - a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med. 2012;2:a006346.